elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34334776-021FA68C-49E5-44EF-91DD-D007E4F71FC2
Q34334776-021FA68C-49E5-44EF-91DD-D007E4F71FC2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34334776-021FA68C-49E5-44EF-91DD-D007E4F71FC2
Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.
P2860
Q34334776-021FA68C-49E5-44EF-91DD-D007E4F71FC2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34334776-021FA68C-49E5-44EF-91DD-D007E4F71FC2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d165c7d9d6e1ffb6ce4f530945523e75dd5a545c
P2860
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.